How to buy DBV Technologies stock (DBVT)

DBV Technologies is a biotechnology business based in the US. DBV Technologies shares (DBVT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.04 – a decrease of 0.33% over the previous week. DBV Technologies employs 108 staff and has a trailing 12-month revenue of around $12.5 million.

Our top picks for where to buy DBV Technologies stock

Buy DBV Technologies stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

DBV Technologies stock price (NASDAQ: DBVT)

Use our graph to track the performance of DBVT stocks over time.

DBV Technologies shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$3.04
52-week range	$2.20 - $10.70
50-day moving average more info button	$1.45
200-day moving average more info button	$1.18
Wall St. target price	$21.79
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-5.30

Is it a good time to buy DBV Technologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

DBV Technologies price performance over time

Historical closes compared with the close of $3.04 from 2024-12-24

1 week (2024-12-18)	-1.62%
1 month (2024-11-26)	0.33%
3 months (2024-09-25)	-13.14%
6 months (2024-06-25)	-36.75%

1 year (2023-12-22)	-34.00%
2 years (2022-12-23)	-78.89%
3 years (2021-12-23)	16.9
5 years (2019-12-24)	101.9

DBV Technologies financials

Revenue TTM	$12.5 million
Gross profit TTM	$4.8 million
Return on assets TTM	-46.25%
Return on equity TTM	-103.11%
Profit margin	0%
Book value	$0.56
Market Capitalization more info button	$64.5 million

TTM: trailing 12 months

DBV Technologies share dividends

We're not expecting DBV Technologies to pay a dividend over the next 12 months.

Have DBV Technologies's shares ever split?

DBV Technologies's shares were split on a 1:2 basis on 6 June 2024 . So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DBV Technologies shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for DBV Technologies shares which in turn could have impacted DBV Technologies's share price.

DBV Technologies share price volatility

Over the last 12 months, DBV Technologies's shares have ranged in value from as little as $2.2045 up to $10.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DBV Technologies's is 0.864. This would suggest that DBV Technologies's shares are less volatile than average (for this exchange).

DBV Technologies overview

DBV Technologies S. A. , a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.

Frequently asked questions

null
What percentage of DBV Technologies is owned by institutions?
Currently 16.783% of DBV Technologies shares are held by institutions. How many people work for DBV Technologies?
Latest data suggests 108 work at DBV Technologies. When does the fiscal year end for DBV Technologies?
DBV Technologies's fiscal year ends in December. Where is DBV Technologies based?
DBV Technologies's address is: 177-181 Avenue Pierre Brossolette, Montrouge, France, 92120 What is DBV Technologies's ISIN number?
DBV Technologies's international securities identification number is: US23306J1016 What is DBV Technologies's CUSIP number?
DBV Technologies's Committee on Uniform Securities Identification Procedures number is: 23306J101